Home Data Calendar Blog

FATE

Tables

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Common Stock Value 0.100.100.100.100.100.090.090.090.090.090.080.080.070.070.070.070.070.050.050.050.040.040.040.040.030.030.030.030.030.030.020.020.00NANA0.00NANANA
Weighted Average Number Of Diluted Shares Outstanding NA96.70NANANA94.33NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Weighted Average Number Of Shares Outstanding Basic NA96.70NANANA94.33NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Weighted Average Number Of Share Outstanding Basic And Diluted NANA96.34NA95.4194.3393.43NA86.8979.3075.89NA66.9365.2164.92NA54.1953.1352.76NA41.4341.4141.39NA32.0928.8728.78NA28.6523.9220.35NA1.261.241.21NA1.17NANA
Earnings Per Share Basic -0.86-0.79NANA-0.45-0.58NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Earnings Per Share Diluted -0.86-0.79NANA-0.45-0.58NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Earnings Per Share Basic And Diluted NANA-0.68-0.72-0.45-0.58-0.48-0.61-0.68-0.35-0.44-0.37-0.40-0.36-0.30-0.25-0.31-0.37-0.27-0.29-0.26-0.23-0.24-0.21-0.27-0.29-0.29-0.26-0.24-0.33-0.34-0.29-4.81-4.46-2.92-3.51-3.51-2.58-3.43

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Revenue From Contract With Customer Excluding Assessed Tax 14.9818.5518.4117.0714.2213.4111.1415.907.565.462.522.802.432.822.631.661.031.031.031.031.031.031.031.031.031.031.321.081.030.330.000.000.210.290.470.640.531.080.42
Revenues 14.9818.5518.4117.0714.2213.4111.1415.907.565.462.522.802.432.822.631.661.031.031.031.031.031.031.031.031.031.031.321.081.030.330.000.000.210.290.470.640.531.080.42
Operating Expenses 101.37101.6692.8886.4568.8560.1957.3549.3039.0534.1737.0131.8829.5526.9023.0818.4017.7220.6315.0813.2711.3710.6011.008.689.419.039.247.997.357.556.944.905.364.563.834.694.183.823.54
Research And Development Expense 79.8281.3172.1469.5253.1348.0244.8538.9830.6926.6729.2825.2123.2021.6317.7314.1013.6416.8211.489.898.587.937.976.236.806.786.645.435.004.864.523.033.383.072.533.403.31NANA
General And Administrative Expense 21.5520.3520.7416.9415.7212.1712.5010.318.357.507.736.676.355.275.354.314.083.823.603.382.792.673.032.452.612.252.602.562.352.692.421.871.981.491.301.280.86NANA
Operating Income Loss -86.39-83.11-74.47-69.38-54.62-46.78-46.21-33.40-31.49-28.71-34.49-29.08-27.12-24.08-20.45-16.74-16.69-19.61-14.05-12.24-10.34-9.57-9.97-7.65-8.39-8.00-7.92-6.91-6.33-7.22-6.94-4.90-5.15-4.27-3.36-4.04-3.65NANA
Allocated Share Based Compensation Expense 19.4720.5419.3314.5913.5413.2512.988.767.847.246.914.584.574.393.871.781.641.491.380.900.870.970.870.820.780.790.800.480.570.740.870.390.980.110.07NANANANA
Profit Loss -83.56-76.11-65.69-68.62-43.31-55.13-45.09-53.11-58.68-28.07-33.52-28.30-26.61-23.48-19.76-16.03-16.78-19.65-14.13-12.50-10.68NANANANANANANANANANANANANANANANANANA
Net Income Loss -83.56-76.11-65.69-68.62-43.31-55.13-45.09-53.11-58.68-28.07-33.52-28.30-26.61-23.48-19.76-16.03-16.78-19.65-14.13-12.50-10.68-9.64-10.13-7.94-8.74-8.41-8.38-7.45-6.89-7.78-6.98-5.74-6.07-5.53-3.55-4.16-4.11-2.74-3.23

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Assets 749.35807.06858.39921.46984.571015.671045.96622.46626.44653.59321.89302.27340.21199.88220.87213.03219.9583.1693.42105.2972.6773.9585.3395.0549.3049.1858.7067.9676.4083.4849.6555.5823.04NANA11.08NANANA
Liabilities And Stockholders Equity 749.35807.06858.39921.46984.571015.671045.96622.46626.44653.59321.89302.27340.21199.88220.87213.03219.9583.1693.42105.2972.6773.9585.3395.0549.3049.1858.7067.9676.4083.4849.6555.5823.04NANA11.08NANANA
Stockholders Equity 518.00580.48633.39678.84730.33752.07790.10384.44424.37474.11219.22244.76268.04127.53145.84160.47173.9351.8365.0077.1945.7555.2163.8673.1525.3723.1330.7338.0444.9951.0745.1850.85-66.40NANA-52.83NANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Assets Current 535.33599.16599.08633.41693.71713.27804.32494.32496.78540.23208.25227.09305.63165.18186.43205.20213.9380.0390.62102.6070.0471.8683.4493.3247.4047.0956.5765.6574.1981.5748.2654.6519.39NANA9.79NANANA
Cash And Cash Equivalents At Carrying Value 82.0955.2764.74133.58129.1876.65106.41167.35349.13433.0783.3799.81249.5971.44183.03190.51183.2536.1632.9188.9543.2331.0640.6188.6137.1035.8739.4964.8172.8681.1847.8854.0419.083.404.659.095.46NANA
Accounts Receivable Net Current 10.2213.1313.858.687.3110.306.955.513.24NANANANANA0.500.50NANA0.50NANANANANANANANANANANANANANANANANANANANA
Prepaid Expense And Other Assets Current 19.9717.1811.458.837.707.377.245.894.735.104.965.662.813.172.903.692.242.021.491.650.820.851.141.210.781.160.950.840.480.400.380.610.30NANA0.71NANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Property Plant And Equipment Net 109.12103.1297.8691.5374.6259.2147.9532.3120.7115.9311.9011.429.659.228.405.123.802.892.652.552.491.951.751.581.751.941.992.162.071.771.260.810.79NANA1.16NANANA
Long Term Investments 13.9411.9367.94100.66124.88149.5098.28NA13.23NA16.1439.44NANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Assets Noncurrent 0.030.030.030.030.010.010.010.010.010.010.010.010.01NANA0.53NANA0.020.020.020.020.020.020.020.020.020.02NANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Liabilities Current 103.9491.5277.9181.2891.88105.6094.5885.5654.2045.3224.9227.8140.5929.4229.1427.2622.6716.2712.5911.059.728.0516.9015.1914.6814.3313.8913.4412.6011.314.354.609.49NANA4.85NANANA
Accounts Payable Current 9.598.4211.448.616.445.779.006.283.7213.565.175.825.715.415.374.215.243.512.161.682.201.182.470.931.202.001.981.001.281.511.330.68NANANA1.23NANANA
Other Accrued Liabilities Current 18.9012.2913.0311.7110.807.345.745.503.813.153.243.394.452.943.593.262.632.983.402.171.531.941.751.411.270.660.751.000.781.08NA0.79NANANANANANANA
Accrued Liabilities Current 50.1540.5235.1142.4154.0025.7420.9315.5614.7811.6211.7714.7013.849.839.9510.939.648.387.447.255.414.774.703.963.342.352.042.442.322.491.642.04NANANA1.04NANANA
Contract With Customer Liability Current 35.2433.6622.5721.4823.5523.0321.0321.1417.1214.632.922.793.375.056.587.593.251.78NA2.10NANANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Operating Lease Liability Noncurrent 105.16106.59107.94109.24104.36105.41106.5193.9483.1678.6873.8325.23NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Stockholders Equity 518.00580.48633.39678.84730.33752.07790.10384.44424.37474.11219.22244.76268.04127.53145.84160.47173.9351.8365.0077.1945.7555.2163.8673.1525.3723.1330.7338.0444.9951.0745.1850.85-66.40NANA-52.83NANANA
Common Stock Value 0.100.100.100.100.100.090.090.090.090.090.080.080.070.070.070.070.070.050.050.050.040.040.040.040.030.030.030.030.030.030.020.020.00NANA0.00NANANA
Additional Paid In Capital 1515.601494.641470.921448.581430.771409.211392.28941.22927.78918.53636.06628.20623.16456.00450.93445.80443.24304.37297.88295.93252.02250.82249.82248.96NANANANA179.90179.10138.65137.3414.37NANA12.79NANANA
Retained Earnings Accumulated Deficit -994.44-910.88-834.77-769.08-700.46-657.15-602.02-556.93-503.82-445.14-417.06-383.55-355.24-328.63-305.16-285.40-269.37-252.59-232.93-218.80-206.30-195.62-185.97-175.85-167.91-159.17-150.76-142.38-134.94-128.05NA-86.51NANANANANANANA
Accumulated Other Comprehensive Income Loss Net Of Tax -3.25-3.38-2.85-0.76-0.07-0.09-0.260.070.310.620.140.020.050.09NA-0.00-0.01-0.01-0.01-0.00-0.01-0.04-0.03-0.00NANANANANANANANANANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 19.4720.5419.33NA13.5413.2512.98NA7.847.246.91NA4.574.393.87NA1.641.491.38NA0.870.970.87NANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Operating Activities -55.05-53.16-64.61-70.29-33.38-32.11-27.10-20.66-30.7338.84-26.67-25.54-19.84-20.31-17.49-11.02-3.56-11.52-12.55-10.72-9.77NANANANANANANANANANANANANANANANANANA
Net Cash Provided By Used In Investing Activities 80.3840.29-7.0371.2877.96-1.37-471.89-166.03-54.1435.3223.77-110.5236.29-91.988.7516.3813.2813.72-43.8413.2013.64NANANANANANANANANANANANANANANANANANA
Net Cash Provided By Used In Financing Activities 1.493.412.803.427.943.72438.054.910.93275.551.45-13.72161.710.691.261.90137.371.160.3543.248.30NANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Operating Activities -55.05-53.16-64.61-70.29-33.38-32.11-27.10-20.66-30.7338.84-26.67-25.54-19.84-20.31-17.49-11.02-3.56-11.52-12.55-10.72-9.77NANANANANANANANANANANANANANANANANANA
Net Income Loss -83.56-76.11-65.69-68.62-43.31-55.13-45.09-53.11-58.68-28.07-33.52-28.30-26.61-23.48-19.76-16.03-16.78-19.65-14.13-12.50-10.68-9.64-10.13-7.94-8.74-8.41-8.38-7.45-6.89-7.78-6.98-5.74-6.07-5.53-3.55-4.16-4.11-2.74-3.23
Profit Loss -83.56-76.11-65.69-68.62-43.31-55.13-45.09-53.11-58.68-28.07-33.52-28.30-26.61-23.48-19.76-16.03-16.78-19.65-14.13-12.50-10.68NANANANANANANANANANANANANANANANANANA
Depreciation Depletion And Amortization 3.192.962.762.211.521.170.960.860.770.750.700.620.590.540.440.330.310.280.290.290.240.230.210.200.220.230.230.210.190.160.120.130.140.140.160.16NANANA
Increase Decrease In Accounts Receivable -2.90-0.725.171.36-2.993.361.432.271.53NANA0.000.00NANA0.00NANANANANANANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Investing Activities 80.3840.29-7.0371.2877.96-1.37-471.89-166.03-54.1435.3223.77-110.5236.29-91.988.7516.3813.2813.72-43.8413.2013.64NANANANANANANANANANANANANANANANANANA
Payments To Acquire Property Plant And Equipment 8.6810.1310.0818.3714.7313.623.982.270.950.641.072.591.261.791.751.120.720.280.180.800.360.410.150.040.030.210.180.180.660.210.400.150.020.060.010.29NANANA
Payments To Acquire Investments 101.5863.95132.17173.45165.4799.34529.91185.01NANANA142.68NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Net Cash Provided By Used In Financing Activities 1.493.412.803.427.943.72438.054.910.93275.551.45-13.72161.710.691.261.90137.371.160.3543.248.30NANANANANANANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31
Revenues 14.9818.5518.4117.0714.2213.4111.1415.907.565.462.522.802.432.822.631.661.031.031.031.031.031.031.031.031.031.031.321.081.030.330.000.000.210.290.470.640.531.080.42
Janssen Biotech Inc 14.2018.1015.90NA11.2010.908.607.705.603.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd 0.800.402.504.003.002.502.508.101.902.002.502.802.402.501.60NANANANANANANANANANANANANANANANANANANANANANANANA
Janssen Biotech Inc, Research And Development Expense 10.0011.409.80NA7.107.106.806.202.401.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Janssen Biotech Inc, Upfront Fee And Equity Premium 4.206.706.10NA4.103.801.801.503.201.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Research Services, Collaborative Arrangement NANA1.30NA1.501.301.301.401.301.301.701.901.601.7012.80NANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Upfront Fee, Collaborative Arrangement 0.200.201.302.001.501.201.200.600.600.700.800.900.800.806.40NANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Ono Letter Agreement 0.600.201.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 14.9818.5518.4117.0714.2213.4111.1415.907.565.462.522.802.432.822.631.661.031.031.031.031.031.031.031.031.031.031.321.081.030.330.000.000.210.290.470.640.531.080.42
Janssen Biotech Inc 14.2018.1015.90NA11.2010.908.607.705.603.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd 0.800.402.504.003.002.502.508.101.902.002.502.802.402.501.60NANANANANANANANANANANANANANANANANANANANANANANANA
Janssen Biotech Inc, Research And Development Expense 10.0011.409.80NA7.107.106.806.202.401.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Janssen Biotech Inc, Upfront Fee And Equity Premium 4.206.706.10NA4.103.801.801.503.201.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Research Services, Collaborative Arrangement NANA1.30NA1.501.301.301.401.301.301.701.901.601.7012.80NANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Upfront Fee, Collaborative Arrangement 0.200.201.302.001.501.201.200.600.600.700.800.900.800.806.40NANANANANANANANANANANANANANANANANANANANANANANANA
Ono Pharmaceutical Company Ltd, Ono Letter Agreement 0.600.201.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Operating Lease Right Of Use Asset
Current Assets
Accounts Receivable Net Current
NonCurrent Assets
Other Assets Noncurrent
Liabilities
Liabilities Current
Current Liabilities
Operating Lease Liability Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Share Outstanding Basic And Diluted
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('fate:OnoPharmaceuticalCompanyLtd', None, 'us-gaap:CollaborativeArrangement')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('fate:OnoPharmaceuticalCompanyLtd', None, 'us-gaap:CollaborativeArrangement')
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:CounterpartyName
(None,)
Revenuesus-gaap: Counterparty Name
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueMeasurementsRecurring')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Measurement Frequency
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:BalanceSheetLocation, us-gaap:FinancialInstrument
('us-gaap:OtherCurrentAssets', None)
Available For Sale Securities Debt Securitiesus-gaap: Balance Sheet Location, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InvestmentType
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel
(None, 'us-gaap:FairValueInputsLevel2')
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Asset Class, us-gaap: Fair Value By Fair Value Hierarchy Level
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('fate:OnoPharmaceuticalCompanyLtd', None, 'us-gaap:CollaborativeArrangement')
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:CounterpartyName
(None,)
Revenuesus-gaap: Counterparty Name
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('fate:OnoPharmaceuticalCompanyLtd', None, 'us-gaap:CollaborativeArrangement')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name